Диссертация (1140198), страница 16
Текст из файла (страница 16)
J. Earley // J. Clin. Neurophysiol. – 2001. –Vol. 18, № 2. – P. 128−147.34.Allen, R. P.Augmentationoftherestlesslegssyndromewithcarbidopa/levodopa / R. P. Allen, C. J. Earley // Sleep. – 1996. – Vol. 19, № 3. – P. 205–213.35.Allen, R. P. Validation of the Johns Hopkins Restless Legs Severity Scale(JHRLSS) / R.
P. Allen, C. J. Earley //Sleep Med. – 2001. – Vol. 2, № 3. – P.239 – 242.36.Altered dopaminergic profile in the putamen and substantia nigra inrestless leg syndrome / J. R. Connor [et al.] // Brain. – 2009. – Vol. 132. – P. 2403–2412.37.An algorithm for the-management of restless legs syndrome / M. H.
Silber[et al.] // Mayo Clin. Proc. – 2004. – Vol. 79, № 7. – P. 916–922.38.Aquino, C. C. Restless genital syndrome in Parkinson disease /C. C. Aquino, T. Mestre, A. E. Lang // JAMA Neurol. – 2014. – Vol. 71, № 12. – P. 1559–1561.39.Arnulf, I. Morgan Not all that goes ‘bump in the night’ is RLS Leg motorrestlessness in PD / I. Arnulf, J.
Morgan // Neurol. – 2011. – Vol. 77, № 22. –P. 1936–1937.40.Augmentation of restless legs syndrome with long–term tramadol treatment/ R. Vetrugno [et al.] // Mov. Disord. – 2007. – Vol. 22, № 3. – P. 424–427.41.Autosomal dominant restless legs syndrome maps on chromosome 14q / M.Bonati [et al.] //Brain. – 2003. – Vol. 126, № 6. – P.
1485–1492.42.Bang, Y. R. Symptom Persistence after Iron Normalization in Women withRestless Legs Syndrome / Y. R. Bang, H. J. Jeon, H. Y. Park// Psychiatry Investigation.– 2018. – Vol. 15, № 4. – P. 390-395.9443.Bastia, J. K. Neuropathy in a cohort of restless leg syndrome patients /J. K. Bastia, S. K. Bhoi, J. Kalita // J. Clin.
Neurosci. – 2015. – Vol. 22, № 8. – P. 1314–8.44.Becker, P. M. Dopaminergic agents in restless legs syndrome and periodiclimb movements of sleep: response and complications of extended treatment in 49 cases/ P. M. Becker, A. O. Jamieson, W. D. Brown // Sleep. – 1993. – Vol. 16, № 8. – P. 713–716.45.Brodeur, C.
Treatment of RLS and PMS with L-dopa: a double-blindcontrolled study / C. Brodeur [et al.] // Neurol. – 1933. – Vol. 35. – P. 1845–1848.46.Calloway, M. Development and validation of a subjective post sleep diary(SPSD) to assess sleep status in subjects with restless legs syndrome / M. Calloway,M. Bharmal, C.Hill-Zabala // Sleep Med. – 2011. – Vol. 12, № 7. – P.
704–710.47.Cho, Y. W. Assessing health-related quality of life in patients with restlesslegs syndrome in Korea: comparison with other chronic medical diseases / Y. W. Cho, D.H. Kim, R.P. Allen // Sleep Med. – 2012. – Vol. 13, № 9. – P. 1158–1163.48.Circadian rhythm of periodic limb movements and sensory symptoms ofrestless legs syndrome / C. Trenkwalder [et al.] // Mov. Disord.
– 1999. – Vol. 14, № 1.–P. 102–110.49.Clemens, S. / Restless legs syndrome. Revisiting the dopamine hypothesisfrom the spinal cord prespective / S. Clemens, D. Rye, S. Hochman // Neurology. –2006. – Vol. 67. – P. 125–130.50.Clinical characteristics and associated comorbidities in diabetic patients withrestless legs syndrome / D.
Greco [et al.] // Exp. Clin. Endocrinol. Diabetes. – 2009. –Vol. 117, №9. – P. 496–499.51.Clinical characteristics and frequency of the hereditary restless legssyndrome in a population of 300 patients / J. W. Winkelman [et al.] // Sleep. – 2000. –Vol. 23, № 5. – P. 597–602.52.Clinical experience with pramipexole in the treatment of restless legssyndrome / G. Merlino [et al.] // Expert Opin Drug Metab Toxicol. – 2008. – Vol. 4, № 2.– P.
225–235.9553.Clinical significance of RLS / W. A. Hening [et al.] // Mov Disord. – 2007–Vol. 22, № 18. – P. 395–400.54.Connor, J. R. Iron and restless legs syndrome: Treatment, genetics andpathophysiology / J. R. Connor, S. Patton // Sleep Med. – 2017. – Vol. 31. – P. 61–70.55.Controlled withdrawal of pramipexole after 6 months of open-labeltreatment in patients with restless legs syndrome / C. Trenkwalder [et al.] // MovementDisorders. –2006. – Vol. 21, № 9. – P.
1404–1410.56.Cynthia, L. C. Treatment of Restless Legs Syndrome / L. C. Cynthia //Neurotherapeutics. – 2014. – Vol. 11, № 1. – P. 177–187.57.Diagnostic indicators of restless legs syndrome in primary careconsultations: the DESYR study / A. Crochard [et al.] // Mov. Disord. – 2007. – Vol.
22,№ 6. – P. 791−797.58.Dopamine agonists for the treatment of restless legs syndrome[Электронныйресурс] / H. Scholz [et al.] // Cochrane Database Syst. Rev. – 2011. –Vol. 16, № 3. – Режим доступа: http://www.ncbi.nlm.nih.gov/pubmed/21412893(датаобращения 06.10.2016).59.Earley, C. J.
Pergolide and carbidopa/levodopa treatment of the restless legssyndrome and periodic leg movements in sleep in a consecutive series of patients / C. J.Earley // Sleep. – 1996. – Vol. 19, №10, P. 801–810.60.Earley, C. J. Restless Legs Syndrome / C.
J. Earley // N. Engl. J. Med. –2003. – Vol. 348, № 21. – P. 2103–2109.61.Earley, C. J. MRI-determined regional brain iron concentration in early-and-late-onset restless legs syndrome /C. J. Earley, P. B. Barker //Sleep Med.– 2006. – Vol.7.– P. 459-461.62.Effect of pramipexole on RLS symptoms and sleep: A randomized, double–blind, placebo–controlled trial / L. Ferini-Strambi [et al.] // Sleep Med. – 2008. – Vol.
9,№ 8. – P. 874–881.63.Effects of immobility on sensory and motor symptoms of restless legssyndrome / M. Michaud [et al.] // Mov. Disord. – 2002. – Vol. 17, № 1. – P. 112–115.64.Efficacy and safety of pramipexole in idiopathic restless legs syndrome: A96polysomnographic dose–finding study – the PRELUDE study / M. Partinen [et al.] //Sleep Med. – 2006. – Vol. 7, № 5. – P. 407–417.65.Efficacy and safety of pramipexole in Japanese patients with primaryrestless legs syndrome: A polysomnographic randomized, double-blind, placebocontrolled study / Y.
Inoue [et al.] // Sleep Med. – 2010. – Vol. 11, № 1. – P. 11–16.66.Efficacy and safety of pramipexole in restless legs syndrome /J. W. Winkelman [et al.] // Neurology. – 2006. – Vol. 67, № 6. – P. 1034–1039.67.Efficacy of pramipexole in restless legs syndrome: A six–week, multicenter,randomized, double-blind study (Effect-RLS Study) / W.
Oertel [et al.] // Mov. Disord. –2007. – Vol. 22, № 2. – P. 213–219.68.Efficacy, safety and dose-response of pramipexole in Japanese patients withprimary restless legs syndrome: Randomized trial / Y. Inoue [et al.] //Neuropsychobiology. – 2011. – Vol. 63, № 35. – P. 42.69.Ekbom, K. A. Restless legs syndrome / K. A. Ekbom // Neurology.
– 1960.– № 10. – P. 868–873.70.Ekbom, K. A. Restless legs: A clinical study / K. A. Ekbom // Acta. Med.Scand. – 1945. – Vol. 158, № 1. – P. 5–123.71.Electrodiagnostic reference values for upper and lower limb nerveconduction studies in adult populations / S. Chen [et al.] // Muscle Nerve. – 2016. – Vol.54, № 3. – P.
371–377.72.Epidemiology of restless legs in The Netherlands / R. Rijsman [et al.] // Eur.J. Neurol. – 2004. – Vol. 11. – № 9. – P. 607–611.73.Epidemiology of restless legs symptoms in adults / B. Phillips [et al.] // Arch.Intern. Med. – 2000. – Vol. 160, № 14. – P. 2137–2141.74.Evans, A. H.
Dopamine dysregulation syndrome in Parkinson’s disease / A.H. Evans, A. J. Lees // Curr. Opin. Neurol. – 2004. – Vol. 17, № 4. – P. 393–398.75.Fukunishi, I. Facial paresthesias resembling restless legs syndrome in apatient on hemodialysis / I. Fukunishi, T. Kitaoka, T. Shirai // Nephron. – 1998. – Vol. 79,№ 4. – P.
485.76.Garcia-Borreguero, D. Restless legs syndrome and PD: a review of the97evidence for a possible association / D. Garcia-Borreguero, P. Odin, C. Serrano //Neurology. – 2003. –Vol. 61, № 6. – P. 49–55.77.Gemignani, F. Restless legs syndrome and painful neuropathy–retrospectivestudy. A role for nociceptive deafferentation? / F. Gemignani, F. Brindani, F. Vitetta //Pain Med. – 2009. – Vol. 10, № 8.
– P. 1481–1486.78.Genetics of restless legs syndrome/ F. J. Jiménez-Jiménez [et al.] // SleepMed. Rew. – 2018. – Vol. 39. – P. 108–121.79.Gjerstad M. D. Increased risk ofleg motor restlessness but not RLS in earlyParkinson disease / M. D. Gjerstad, O. B. Tysnes, J. P. Larsen//Neurology. – 2011. – Vol.77, № 22. – P.
1941–1946.80.Gorson, K. C. Idiopathic distal small fiber neuropathy / K. C. Gorson, A. H.Ropper // Acta. Neurol. Scand. – 1995. – Vol. 92, № 5. – P. 376–382.81.Grote, L. A randomized, double-blind, placebo controlled, multi-centerstudy of intravenous iron sucrose and placebo in the treatment of restless legs syndrome/ L. Grote, L. Leissner, J. Hedner, J. Ulfberg // Mov Disord. – 2009.
– Vol. 24, № 10. –P. 1445 – 1452.82.Hanson, M. Analysis of familial and sporadic restless legs syndrome in ageof onset, gender, and severity features / M. Hanson, M. Honour, A. Singleton // J. Neurol.– 2004. – Vol. 251, № 11. – P. 1398–1401.83.Happe, S. Treatment of idiopathic restless legs syndrome with gabapentin /S. Happe, G. Klosch, B. Saletu // Neurology. – 2001. – Vol. 57, № 9. – P. 1717–1719.84.Hattan, E. Is there a higher risk of restless legs syndrome in peripheralneuropathy? / E. Hattan, C. Chalk, R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
